Brevan Howard Capital Management LP
Position in KROS — Keros Therapeutics, Inc.
CIK 1512857
ST. HELIER, Y9
Position in KROS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$161,747
-$548,159 QoQ
Shares Held
14,651
-67.4% QoQ
Ownership
0.074%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KROS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Brevan Howard Capital Management LP holds $183,834,510 across 129 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
517,621 | $18,318,607 | |
| 2 | MRNA |
Moderna, Inc.
|
181,105 | $12,682,782 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
155,727 | $11,598,546 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,622 | $8,753,376 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
31,928 | $7,815,015 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
156,812 | $7,376,435 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
309,065 | $6,756,160 | |
| 8 | INCY |
Incyte Corp
|
45,270 | $5,131,807 |
All Filings in KROS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $161,747 | 14,651 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $709,906 | 44,874 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $936,489 | 70,149 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $670,950 | 65,844 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $177,074 | 11,186 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $332,044 | 5,718 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||